Total Payments
$627,084
2024 Payments
$266,245
Companies
33
Transactions
922
Medicare Patients
11,913
Medicare Billing
$11.8M
Payment Breakdown by Category
Other$462,591 (73.8%)
Consulting$72,515 (11.6%)
Travel$65,103 (10.4%)
Food & Beverage$26,805 (4.3%)
Gifts$38.80 (0.0%)
Education$31.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $410,960 | 106 | 65.5% |
| Consulting Fee | $72,515 | 30 | 11.6% |
| Travel and Lodging | $65,103 | 212 | 10.4% |
| Honoraria | $51,631 | 24 | 8.2% |
| Food and Beverage | $26,805 | 547 | 4.3% |
| Gift | $38.80 | 2 | 0.0% |
| Education | $31.60 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $198,361 | 240 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $116,738 | 123 | $0 (2024) |
| Genentech USA, Inc. | $105,181 | 161 | $0 (2024) |
| Astellas Pharma US Inc | $85,711 | 85 | $0 (2024) |
| Alimera Sciences, Inc. | $49,390 | 87 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $36,057 | 54 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $12,675 | 18 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $5,503 | 20 | $0 (2024) |
| Allergan, Inc. | $5,428 | 39 | $0 (2021) |
| F. Hoffmann-La Roche AG | $4,572 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $266,245 | 283 | Regeneron Healthcare Solutions, Inc. ($95,396) |
| 2023 | $176,403 | 200 | Regeneron Healthcare Solutions, Inc. ($61,806) |
| 2022 | $73,413 | 142 | Genentech USA, Inc. ($28,961) |
| 2021 | $35,553 | 77 | Alimera Sciences, Inc. ($17,867) |
| 2020 | $17,690 | 42 | Regeneron Healthcare Solutions, Inc. ($13,039) |
| 2019 | $42,611 | 77 | Novartis Pharmaceuticals Corporation ($30,105) |
| 2018 | $6,907 | 53 | Allergan Inc. ($4,588) |
| 2017 | $8,263 | 48 | Alimera Sciences, Inc. ($7,010) |
All Payment Transactions
922 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,896.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,896.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,448.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $72.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,120.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/18/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Ophthalmology | ||||||
| 12/17/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Ophthalmology | ||||||
| 12/16/2024 | Apellis Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $4,536.00 | General |
| 12/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $5.93 | General |
| Category: Ophthalmology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,520.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $995.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $495.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $490.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $146.18 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $133.87 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,520.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/07/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $526.03 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/07/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $450.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $1.84 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $362.07 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | Cash or cash equivalent | $84.42 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $28.26 | General |
| Category: Ophthalmology | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $109.57 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 3,092 | 48,460 | $12.9M | $2.9M |
| 2022 | 16 | 3,035 | 18,902 | $13.3M | $2.9M |
| 2021 | 16 | 2,769 | 13,509 | $12.7M | $2.9M |
| 2020 | 14 | 3,017 | 13,458 | $12.1M | $3.0M |
Total Patients
11,913
Total Services
94,329
Medicare Billing
$11.8M
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 107 | 38,160 | $4.1M | $1.1M | 26.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 120 | 1,224 | $2.6M | $841,706 | 32.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 104 | 2,308 | $2.5M | $417,614 | 16.7% |
| 67028 | Injection of drug into eye | Office | 2023 | 357 | 1,680 | $2.5M | $161,498 | 6.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 745 | 969 | $247,095 | $83,455 | 33.8% |
| J3490 | Unclassified drugs | Office | 2023 | 26 | 45 | $168,750 | $78,828 | 46.7% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 20 | 483 | $179,676 | $74,978 | 41.7% |
| 92134 | Imaging of retina | Office | 2023 | 840 | 2,315 | $298,636 | $70,780 | 23.7% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 13 | 255 | $74,460 | $30,692 | 41.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 226 | 341 | $59,675 | $22,987 | 38.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 175 | 175 | $70,000 | $19,154 | 27.4% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 13 | 13 | $89,570 | $12,037 | 13.4% |
| 92250 | Photography of the retina | Office | 2023 | 270 | 370 | $74,000 | $9,927 | 13.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 38 | 38 | $10,830 | $3,890 | 35.9% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 25 | 70 | $21,000 | $3,339 | 15.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 13 | 14 | $5,054 | $494.01 | 9.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 120 | 1,530 | $3.2M | $1.1M | 34.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 168 | 4,529 | $4.9M | $999,864 | 20.4% |
| J3590 | Unclassified biologics | Office | 2022 | 26 | 110 | $708,290 | $198,957 | 28.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 336 | 1,892 | $2.8M | $181,766 | 6.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 42 | 5,760 | $618,106 | $171,886 | 27.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 720 | 976 | $248,880 | $83,899 | 33.7% |
| 92134 | Imaging of retina | Office | 2022 | 835 | 2,667 | $344,043 | $82,237 | 23.9% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 20 | 322 | $119,784 | $50,147 | 41.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 271 | 380 | $66,500 | $24,774 | 37.3% |
About Dr. David Chin Yee, MD
Dr. David Chin Yee, MD is a Retina Specialist healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2009. The National Provider Identifier (NPI) number assigned to this provider is 1740424563.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Chin Yee, MD has received a total of $627,084 in payments from pharmaceutical and medical device companies, with $266,245 received in 2024. These payments were reported across 922 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($410,960).
As a Medicare-enrolled provider, Chin Yee has provided services to 11,913 Medicare beneficiaries, totaling 94,329 services with total Medicare billing of $11.8M. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Atlanta, GA
- Active Since 04/23/2009
- Last Updated 03/23/2023
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1740424563
Products in Payments
- EYLEA HD (Biological) $150,773
- Syfovre (Drug) $80,428
- Izervay (Drug) $75,546
- Vabysmo (Drug) $63,536
- EYLEA (Biological) $59,501
- ILUVIEN (Drug) $36,905
- VABYSMO (Drug) $24,947
- Lucentis (Biological) $14,104
- Iluvien (Drug) $9,629
- BEOVU (Drug) $8,060
- OZURDEX (Drug) $5,939
- EYP-1901 (Drug) $3,451
- YUTIQ (Drug) $2,057
- Iluvien (Biological) $1,463
- EYLEA AFLIBERCEPT INJECTION (Biological) $716.98
- ForeseeHome (Device) $538.46
- NGENUITY (Device) $523.46
- Constellation (Device) $430.46
- XIPERE (Drug) $398.50
- SUSVIMO (Drug) $365.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.